Comments on: Life sciences briefing: Thursday, Jan. 17, 2007 http://venturebeat.com/2008/01/17/life-sciences-briefing-thursday-jan-17-2007/ News About Tech, Money and Innovation Wed, 25 Nov 2009 08:36:57 +0000 http://wordpress.org/?v=2.8.5 hourly 1 By: Life-science briefing: Tuesday, March 18, 2008 » VentureBeat http://venturebeat.com/2008/01/17/life-sciences-briefing-thursday-jan-17-2007/comment-page-1/#comment-799258 Life-science briefing: Tuesday, March 18, 2008 » VentureBeat Tue, 18 Mar 2008 15:26:25 +0000 http://venturebeat.com/2008/01/17/life-sciences-briefing-thursday-jan-17-2007/#comment-799258 [...] written before about Alimera, which is presumably still contemplating an IPO this fall. All five of the company’s existing VC backers participated in the round: BA Venture [...] [...] written before about Alimera, which is presumably still contemplating an IPO this fall. All five of the company’s existing VC backers participated in the round: BA Venture [...]

]]> By: David P. Hamilton http://venturebeat.com/2008/01/17/life-sciences-briefing-thursday-jan-17-2007/comment-page-1/#comment-741316 David P. Hamilton Fri, 18 Jan 2008 19:15:26 +0000 http://venturebeat.com/2008/01/17/life-sciences-briefing-thursday-jan-17-2007/#comment-741316 Thanks for the comment. I frequently use the term "stem cell" in a broad sense to include any precursor cell that retains the capability to differentiate. Myoblasts qualify by this definition, although they're clearly not embryonic stem cells. Hope that clears up any confusion. Thanks for the comment. I frequently use the term “stem cell” in a broad sense to include any precursor cell that retains the capability to differentiate. Myoblasts qualify by this definition, although they’re clearly not embryonic stem cells. Hope that clears up any confusion.

]]> By: Jon Rowley http://venturebeat.com/2008/01/17/life-sciences-briefing-thursday-jan-17-2007/comment-page-1/#comment-741232 Jon Rowley Fri, 18 Jan 2008 18:01:05 +0000 http://venturebeat.com/2008/01/17/life-sciences-briefing-thursday-jan-17-2007/#comment-741232 Hi David, just a friendly edit - Bioheart is not into stem cells really. Their lead product is based on cultured autologous myoblasts (muscle cells isolated from the patients muscle), not stem cells. It may be more correct to say "Cellular therapy developer". Love the site - Regards from The Regeneration Station; http://regeneration-station.com Hi David,

just a friendly edit – Bioheart is not into stem cells really. Their lead product is based on cultured autologous myoblasts (muscle cells isolated from the patients muscle), not stem cells. It may be more correct to say “Cellular therapy developer”.

Love the site -

Regards from The Regeneration Station; http://regeneration-station.com

]]>